The treatment landscape of metastatic castrate-resistant prostate cancer (mCRPC) is continually evolving. In this podcast, an advanced practice provider discusses recent evidence on PARP inhibitors for mCRPC and how they incorporate these data into clinical practice.
Topics include the role of PARP inhibitors for mCRPC with mutations in homologous recombination repair genes, testing for BRCA1/2 and other homologous recombination repair mutations, approved indications for olaparib and rucaparib, managing adverse events with approved PARP inhibitors, and a look at the future of PARP inhibition in mCRPC.
Oncology NPs, PAs, and nurses
This activity is supported by educational grants from AstraZeneca; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; and Merck Sharp & Dohme Corp.
Brenda Martone, MSN, ANP-BC, AOCNP, has no relevant financial relationships to disclose.
© 2022 Practicing Clinicians Exchange. All Rights Reserved. 104922O-pod2